|
TANAKA Junji
Department Other, Other Position |
|
| Article types | Review article |
| Language | English |
| Peer review | Peer reviewed |
| Title | Recent advances in cellular therapy for malignant lymphoma. |
| Journal | Formal name：Cytotherapy Abbreviation：Cytotherapy ISSN code：14772566/14653249 |
| Domestic / Foregin | Foregin |
| Volume, Issue, Page | 23,pp.662-671 |
| Author and coauthor | Tanaka Junji†* |
| Authorship | Lead author,Corresponding author |
| Publication date | 2021/08 |
| Summary | Cellular therapies for malignant lymphoma include autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and adaptive cellular therapy using EBV-specific T cells, cytokine-induced killer (CIK) cells, NKT cells, NK cells, chimeric antigen receptor T (CAR-T) cells and chimeric antigen receptor NK (CAR-NK) cells. In this review we discusses recent advances of these cellular therapies and consider ways to optimize these therapies. Not only a single strategy using one of these cellular therapies, but also multi-disciplinary treatment combines with antibodies, such as an anti-tumor antibody and an immune checkpoint antibody, may be more effective for relapsed and refractory lymphoma. |
| DOI | 10.1016/j.jcyt.2020.12.007 |
| PMID | 33558145 |